BioPharma Dive July 1, 2021
Shoshana Dubnow

A five-year alliance with ElevateBio is designed to get around a bottleneck that has held back the institution’s gene therapy work.

ElevateBio, a privately held biotech with hefty financial backing, has formed a five-year alliance with Boston Children’s Hospital that could lead to the creation of several new gene and cell therapy startups.

The agreement gives Boston Children’s researchers access to a suite of scientific tools and ElevateBio’s 140,000-square-foot manufacturing facility in Waltham, Massachusetts. That assistance should help Boston Children’s speed development of gene therapy research that the institution has struggled to progress into clinical testing.

“We’re not a drug company,” said David Williams, chief of Boston Children’s hematology and oncology division, in an interview. “We’ve looked for ways...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Health System / Hospital, Pharma / Biotech, Provider
Aviv Regev: The Revolution in Digital Biology
Global Inequities In Access To Drugs Costs Millions Of Lives Each Year
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
Why Conflicts Of Interest May Not Be As Bad As You Think (And Besides We All Have Them!)

Share This Article